Dr. Hagop Kantarjian - CML- Chronic myeloid leukemia
''Hagop Kantarjian, MD serves as Clinical Consultant of Astex Therapeutics Limited. Dr. Kantarjian serves as the Chairman of the Leukemia Department and a Professor of Medicine of the University of Texas, MD Anderson Cancer Center. He has been associated with MD Anderson Cancer Center since 1981. Dr. Kantarjian is a leading expert in the field of chronic and acute leukemia and was a key investigator in clinical trials that led to the approval of Gleevec as a treatment ...''
Extract of Bloomberg Businessweek
VIDEOS
ASH 2010 Acute Leukemia Hagop Kantarjian, MD, PhD The University of Texas
December 2010, Oncology Tube
Newer Drugs Improve Upon Gleevec for Chronic Myeloid Leukemia
June 4, 2010, mdandersonorg
ASH 2010 Acute Leukemia Hagop Kantarjian, MD, PhD The University of Texas
December 2010, Oncology Tube
Newer Drugs Improve Upon Gleevec for Chronic Myeloid Leukemia
June 4, 2010, mdandersonorg
ARTICLES
MD Anderson’s Hagop Kantarjian, M.D., awarded highest honor from American Society of Clinical Oncology
April 26, 2023, EurekAlert
How I treat newly diagnosed chronic phase CML
August 16, 2012, Journal Blood
Front-Line Therapy for CML (diaporama)
April 2012, First ME Hematology forum
MD Anderson’s Hagop Kantarjian, M.D., awarded highest honor from American Society of Clinical Oncology
April 26, 2023, EurekAlert
How I treat newly diagnosed chronic phase CML
August 16, 2012, Journal Blood
Front-Line Therapy for CML (diaporama)
April 2012, First ME Hematology forum